BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Bio-Path Holdings\, Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Bio-Path Holdings\, Inc.'s drugs 
 run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT02781883-2931@assetmemo.bio
DTSTAMP:20261121T005925Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Prexigebersen: Phase 2 readout est. (NCT02781883)
DESCRIPTION:Prexigebersen\, phase 2\, Acute Myeloid Leukemia.\nStudy: Clini
 cal Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in
  AML\nEstimated primary completion: December 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/prexigebersen#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT02781883
URL:https://assetmemo.bio/drug/prexigebersen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
